Page 24 - Cipla
Cipla plans to get more aggressive in US, UK
The market size for blockbuster inhaler Seretide in Britain was $400 million last year, say analysts
 "Cipla plans to get more aggressive in US, UK")
Cipla Q2 profit falls as Europe, emerging markets suffer
Sales in India, Cipla's biggest market, rose 21% in the quarter
 "Cipla Q2 profit falls as Europe, emerging markets suffer")
Cipla is back to old strategy with a twist
US likely to bring significant growth
 "Cipla is back to old strategy with a twist")
Blow to Cipla; company loses court battle in drug-overcharging case
Company had received notices of demand aggregating to Rs 1,768 cr
Cipla signs deal to set up first biosimilars unit in South Africa
The agreement with KwaZulu-Natal Dube Trade Port SEZ for Cipla BIOTEC's new facility was concluded during the BRICS Summit
Cipla gains as Indore plant gets US FDA clearance
The stock was up 3% to Rs 596 on the BSE in early morning trade.
 "Cipla gains as Indore plant gets US FDA clearance")
Cipla's Indore plant cleared by FDA
The clearance indicates the formal closure of the US FDA inspection conducted in July/August, 2015
Concerns aggravate for Cipla, Alkem
More worries for Alkem, as its Daman plant, which is under scanner, is crucial for US growth
Cipla falls on heavy volumes
The stock dipped 6% to Rs 562 in intra-day trade on media reports that the USFDA inspected the company's Goa facility.
Drug firms facing challenging times due to price control: Cipla
Tightening of new product registration procedures also impacting industry
 "Drug firms facing challenging times due to price control: Cipla")
Cipla gets USFDA nod for generic anti-depressant drug
Company's shares were today trading at Rs 570.25 per scrip in the afternoon trade on BSE, up 0.54% from its previous close
Cipla, Godrej recognised in Fortune Change the World list
Fortune lauded Cipla for driving prices down for much-needed medications
Street positive on Cipla despite weak results
Base business growth in the US, and bottoming out of operating-profit margins are key positives
 "Street positive on Cipla despite weak results")
Cipla gains post June quarter results
The stock was up 5% at Rs 540 on the NSE, as compared to 0.57% fall in the Nifty 50 index at 12:49 pm.
Cipla's net profit dips 44%, announces new CEO
Overall revenue of Cipla falls 6%; international business drops 14%
Cipla first quarter profit lags estimates; names new CEO
Cipla's April-June net profit was 3.65 billion rupees, compared with 6.49 billion rupees a year earlier
Cipla appoints Kedar Upadhye as Global CFO
Earlier, he has worked with Pepsi India and Thermax Group
 "Cipla appoints Kedar Upadhye as Global CFO")
Cipla told to deposit Rs 175 crore in drug overcharging case
The case pertains to 2003 when Cipla received a demand notice from the National Pharmaceutical Pricing Authority for alleged overcharging of drugs covered under price cap
Cipla to set up biotech plant in South Africa
Cipla Biotech, a subsidiary of the company, will construct the plant at a special economic zone in Durban and will commence production in 2018
Cipla: Short-term pain despite strong base
Cipla has missed analysts' expectation by 30 per cent at the EBITDA level for the year
 "Cipla: Short-term pain despite strong base")
